The global Biliary Tract Cancers (BTCs) Treatment Market is expected to garner a market value of US$ 3.2 Billion in 2023 and is expected to accumulate a market value of US$ 4.74 Billion by registering a CAGR of 4% in the forecast period 2023 to 2033. The market for Biliary Tract Cancers (BTCs) Treatment registered a CAGR of 3% in the historical period 2018 to 2022.
The Biliary Tract Cancers (BTCs) Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The Biliary Tract Cancers (BTCs) Treatment market offers a range of products and services for its effective management and treatments including medications such as chemotherapy, chemotherapy drugs such as gemcitabine and cisplatin, surgery, and radiation therapy.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3.2 Billion |
| Anticipated Forecast Value (2033) | US$ 4.74 Billion |
| Projected Growth Rate (2023 to 2033) | 4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Biliary Tract Cancers (BTCs) Treatment reflected a value of 3% during the historical period, 2018 to 2022. During this period, the demand for treatment for Biliary Tract Cancers (BTCs) increased, as it is a group of rare but aggressive cancers that originate in the biliary tract, which includes the bile ducts, gallbladder, and ampulla of Vater. The treatment of BTCs typically involves surgery, chemotherapy, and radiation therapy, depending on the stage and location of the cancer.
Moving forward, it is expected that the Biliary Tract Cancers (BTCs) Treatment market will continue to grow significantly in the coming years, driven by factors such as an increase in the incidence of BTCs, the development of new treatment options, and a growing demand for effective therapies.
Overall, the demand for Biliary Tract Cancers (BTCs) Treatment is expected to increase in the forecast period of 2023 to 2033, driven by a growing need for effective solutions to prevent and manage Biliary Tract Cancers (BTCs). In recent years, several new treatment options have emerged for BTCs, including targeted therapies and immunotherapies. Targeted therapies are drugs that specifically target the molecular pathways that are involved in the growth and spread of cancer cells. Immunotherapies, on the other hand, use the body's own immune system to fight cancer cells.
Furthermore, in the years to come, driven by a combination of factors such as an increase in the incidence of BTCs, the development of new treatment options, and a growing demand for effective therapies, the market for Biliary Tract Cancers (BTCs) Treatment is expected to register a CAGR of 4% in the forecast period 2023 to 2033.
Growing advancements in diagnostic and treatment options to push the market growth
The Biliary Tract Cancers (BTCs) Treatment Market is expected to experience significant growth in the coming years, driven by several factors. Firstly, the incidence of BTCs is increasing globally, particularly in developed countries such as the United States and European countries. This increase is partly due to the rise in risk factors such as obesity, diabetes, and chronic liver diseases, which are associated with the development of BTCs.
Additionally, there is a growing demand for effective treatment options for BTCs, given the poor prognosis associated with these cancers. This demand is driving the development of new drugs and therapies, including targeted therapies and immunotherapies. The aging population is also contributing to the growth of the BTCs treatment market. As people age, their risk of developing BTCs increases, leading to a higher demand for treatment options.
Furthermore, advancements in diagnostic techniques, such as imaging and biomarker testing, are improving the early detection of BTCs, which can lead to better outcomes and increased demand for treatment. Increasing investment in research and development by pharmaceutical and biotech companies is also contributing to the growth of the BTCs treatment market. These companies are developing new drugs and therapies that target specific molecular pathways involved in the development and progression of BTCs.
Overall, the combination of these factors is expected to drive significant growth in the BTCs treatment market in the coming years.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
One of the biggest challenges in managing Biliary Tract Cancers (BTCs) is the lack of awareness about the condition and its health consequences. Awareness of BTCs is relatively low among the general public and healthcare providers, which can delay diagnosis and treatment.
While there are several treatment options available for Biliary Tract Cancers (BTCs), there is still a need for more effective and innovative solutions. The cost of treatment for BTCs can be high, particularly for newer drugs and therapies. This can limit access to treatment, particularly in developing countries.
Furthermore, regulatory challenges can limit the development and approval of new drugs and therapies for BTCs, which can slow down progress in the field.
Increasing Advancements in the Diagnostic Techniques Shaping Landscape for Biliary Tract Cancers (BTCs) Treatment in South & East Asia
The Biliary Tract Cancers (BTCs) Treatment Market in the South and East Asia region is growing, driven by several factors such as the increasing incidence of BTCs, growing awareness about the disease, and advancements in diagnostic techniques.
In South and East Asia, liver fluke infection is a common cause of BTCs, particularly in Thailand, Vietnam, and parts of China. As a result, these countries have a high incidence of BTCs, leading to a growing demand for effective treatment options.
In addition, there is a growing awareness about the disease in the region, which is leading to more frequent diagnoses and better access to treatment. Governments and healthcare organizations are also taking steps to improve the diagnosis and treatment of BTCs, which is helping to drive growth in the market. Advancements in diagnostic techniques, such as imaging and biomarker testing, are also improving the early detection of BTCs, leading to better outcomes and increased demand for treatment.
Increasing Focus on Technological advancements Shaping Landscape for Biliary Tract Cancers (BTCs) Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising incidence of BTCs in North America, which is driving the demand for effective treatment options. This is partly due to risk factors such as obesity, diabetes, and chronic liver diseases.
Additionally, North America has a well-developed healthcare infrastructure which is leading to improvements in imaging and biomarker testing enabling earlier detection of BTCs, leading to better outcomes and increased demand for treatment. Governments in North America are implementing initiatives to improve the detection and treatment of BTCs, which is driving demand for effective therapies.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Injectable segment to hold a significant share and push market growth
According to various reports and studies, the injectable segment is expected to grow due to the increasing prevalence of BTCs, which is driving demand for these drugs.
Furthermore, advancements in drug delivery technologies such as novel drug delivery systems, including drug-eluting stents, nanotechnology-based drug delivery, and implantable drug delivery systems, are also expected to boost the growth of the injectable segment in the BTCs treatment market.
Overall, the injectable segment is likely to account for a significant share of the BTCs treatment market due to its effectiveness in delivering many of the drugs used to treat the disease and the increasing demand for these drugs.
Durvalumab to take the lead and drive market growth
Durvalumab is likely to account for a significant share in the biliary tract cancers (BTCs) treatment market. Durvalumab is an immune checkpoint inhibitor that works by blocking the PD-L1 protein on cancer cells, which helps the immune system to recognize and attack the cancer cells.
In 2020, the US FDA approved Durvalumab in combination with chemotherapy as a first-line treatment for advanced or metastatic BTCs, making it the first immunotherapy-based treatment approved for this indication. This approval has significantly boosted the market share of Durvalumab in the BTCs treatment market.
Key players in the market include companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, and BeiGene, along with healthcare providers and technology companies among other global players.
The demographics of the trial showed that 56% were Asian, 37% were White, 2% were Black, and 4% were of other races, while 7% were Hispanic or Latino. In terms of gender, 50% were male and 50% were female, with a median age of 64 years (ranging from 20-85). 47% of the participants were 65 years or older. In the trial, 56% of patients had intrahepatic cholangiocarcinoma, 25% had gallbladder cancer, and 19% had extrahepatic cholangiocarcinoma.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3.2 Billion |
| Market Value in 2033 | US$ 4.74 Billion |
| Growth Rate | CAGR of 4% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, and BeiGene |
| Customization | Available Upon Request |
The primary consumer for Biliary Tract Cancers (BTCs) Treatment is the healthcare industry.
Some of the key players in the Biliary Tract Cancers (BTCs) Treatment Market include AbbVie, Genentech, Johnson & Johnson, Novartis, and Pfizer.
The market is estimated to secure a valuation of US$ 3.2 billion in 2023.
The market is estimated to reach US$ 4.74 billion by 2033.
The oncology sector holds high revenue potential.
1. Executive Summary | Biliary Tract Cancers (BTCs) Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Durvalumab 5.3.2. Zanidatamab 5.3.3. Ramucirumab 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Inhalation 6.3.2. Intravenous 6.3.3. Intranasal 6.3.4. Subcutaneous 6.3.5. Oral 6.3.6. Parenteral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Molecule Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Molecule Type , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Molecule Type , 2023 to 2033 7.3.1. Antibody 7.3.2. Antisense oligonucleotides 7.3.3. Immunotherapy 7.3.4. Monoclonal antibody 7.3.5. Peptides 7.3.6. Protein 7.3.7. Small molecule 7.3.8. Stem Cell 7.4. Y-o-Y Growth Trend Analysis By Molecule Type , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Molecule Type , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033 8.3.1. Mono 8.3.2. Combination 8.3.3. Mono/Combination 8.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Molecule Type 10.2.5. By Product Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Molecule Type 10.3.5. By Product Type 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Molecule Type 11.2.5. By Product Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Molecule Type 11.3.5. By Product Type 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Molecule Type 12.2.5. By Product Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Molecule Type 12.3.5. By Product Type 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Molecule Type 13.2.5. By Product Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Molecule Type 13.3.5. By Product Type 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Molecule Type 14.2.5. By Product Type 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Molecule Type 14.3.5. By Product Type 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Molecule Type 15.2.5. By Product Type 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Molecule Type 15.3.5. By Product Type 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Route of Administration 16.2.4. By Molecule Type 16.2.5. By Product Type 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Route of Administration 16.3.4. By Molecule Type 16.3.5. By Product Type 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Route of Administration 17.1.2.3. By Molecule Type 17.1.2.4. By Product Type 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Route of Administration 17.2.2.3. By Molecule Type 17.2.2.4. By Product Type 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Route of Administration 17.3.2.3. By Molecule Type 17.3.2.4. By Product Type 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Route of Administration 17.4.2.3. By Molecule Type 17.4.2.4. By Product Type 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Route of Administration 17.5.2.3. By Molecule Type 17.5.2.4. By Product Type 17.6. United kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Route of Administration 17.6.2.3. By Molecule Type 17.6.2.4. By Product Type 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Route of Administration 17.7.2.3. By Molecule Type 17.7.2.4. By Product Type 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Route of Administration 17.8.2.3. By Molecule Type 17.8.2.4. By Product Type 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Route of Administration 17.9.2.3. By Molecule Type 17.9.2.4. By Product Type 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Route of Administration 17.10.2.3. By Molecule Type 17.10.2.4. By Product Type 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Route of Administration 17.11.2.3. By Molecule Type 17.11.2.4. By Product Type 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Route of Administration 17.12.2.3. By Molecule Type 17.12.2.4. By Product Type 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Route of Administration 17.13.2.3. By Molecule Type 17.13.2.4. By Product Type 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Route of Administration 17.14.2.3. By Molecule Type 17.14.2.4. By Product Type 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Route of Administration 17.15.2.3. By Molecule Type 17.15.2.4. By Product Type 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Route of Administration 17.16.2.3. By Molecule Type 17.16.2.4. By Product Type 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Route of Administration 17.17.2.3. By Molecule Type 17.17.2.4. By Product Type 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Route of Administration 17.18.2.3. By Molecule Type 17.18.2.4. By Product Type 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Route of Administration 17.19.2.3. By Molecule Type 17.19.2.4. By Product Type 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Route of Administration 17.20.2.3. By Molecule Type 17.20.2.4. By Product Type 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Route of Administration 17.21.2.3. By Molecule Type 17.21.2.4. By Product Type 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Route of Administration 18.3.4. By Molecule Type 18.3.5. By Product Type 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Incyte Corporation 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Loxo Oncology 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Bayer 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Roche 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Genentech 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. QED Therapeutics 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Agios Pharmaceuticals 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Servier Pharmaceuticals 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Merck Sharp & Dohme 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. AstraZeneca 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Taiho Oncology 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Delcath Systems 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 19.1.13. Eisai 19.1.13.1. Overview 19.1.13.2. Product Portfolio 19.1.13.3. Profitability by Market Segments 19.1.13.4. Sales Footprint 19.1.13.5. Strategy Overview 19.1.13.5.1. Marketing Strategy 19.1.14. TransThera Sciences (Nanjing) 19.1.14.1. Overview 19.1.14.2. Product Portfolio 19.1.14.3. Profitability by Market Segments 19.1.14.4. Sales Footprint 19.1.14.5. Strategy Overview 19.1.14.5.1. Marketing Strategy 19.1.15. Basilea Pharmaceutica 19.1.15.1. Overview 19.1.15.2. Product Portfolio 19.1.15.3. Profitability by Market Segments 19.1.15.4. Sales Footprint 19.1.15.5. Strategy Overview 19.1.15.5.1. Marketing Strategy 19.1.16. Zymeworks 19.1.16.1. Overview 19.1.16.2. Product Portfolio 19.1.16.3. Profitability by Market Segments 19.1.16.4. Sales Footprint 19.1.16.5. Strategy Overview 19.1.16.5.1. Marketing Strategy 19.1.17. BeiGene 19.1.17.1. Overview 19.1.17.2. Product Portfolio 19.1.17.3. Profitability by Market Segments 19.1.17.4. Sales Footprint 19.1.17.5. Strategy Overview 19.1.17.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Biliary Tract Cancers (BTCs) Treatment Market
